Though the company beat Wall Street estimates in the fourth quarter, HCP’s (NYSE: HCP) stock has been pummeled. It lost more than 20% since its earnings announcement on weak 2016 management guidance on challenges that have been already widely reported. The stock clearly has been oversold on panic selling as… Read More